Page last updated: 2024-08-24

capecitabine and Paronychia

capecitabine has been researched along with Paronychia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cubiró, X; Garcia-Muret, MP; Planas-Ciudad, S; Puig, L	1
Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J	1

Trials

1 trial(s) available for capecitabine and Paronychia

Article	Year
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. British journal of cancer, 2000, Volume: 83, Issue:1 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome	2000

Article

Year

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.

British journal of cancer, 2000, Volume: 83, Issue:1

Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome

2000

Other Studies

1 other study(ies) available for capecitabine and Paronychia

Article	Year
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. JAMA dermatology, 2018, 01-01, Volume: 154, Issue:1 Topics: Administration, Topical; Aged; Angiolymphoid Hyperplasia with Eosinophilia; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paronychia; Prognosis; Retrospective Studies; Timolol; Treatment Outcome	2018

Article

Year

Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.

JAMA dermatology, 2018, 01-01, Volume: 154, Issue:1

Topics: Administration, Topical; Aged; Angiolymphoid Hyperplasia with Eosinophilia; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paronychia; Prognosis; Retrospective Studies; Timolol; Treatment Outcome

2018